<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01901497</url>
  </required_header>
  <id_info>
    <org_study_id>NIVnebu</org_study_id>
    <nct_id>NCT01901497</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Nebulized Amikacin in Non Invasive Ventilated Healthy Volunteers.</brief_title>
  <acronym>NIV-NEBU</acronym>
  <official_title>Comparison of Pharmacokinetics of Amikacin Administered by Three Vibrating Mesh Nebulizers in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital St Luc, Brussels</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Haute Ecole de Santé Vaud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ligue Pulmonaire Neuchâteloise</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital St Luc, Brussels</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the pharmacokinetics of nebulized amikacin
      administered with three vibrating mesh nebulizers coupled with a single limb circuit bilevel
      ventilator in healthy volunteers. Following our previous in vitro study, our hypotheses are
      that the pharmacokinetics varies among the devices tested and that a most efficient device
      can be identified.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of nebulized amikacin</measure>
    <time_frame>within the first 24 hours after nebulization</time_frame>
    <description>The area under the urinary amikacin concentration-time curve after nebulization(AUC0-24 hour) is calculated from the data obtained during 24 hours after nebulization. To determine amikacin absorption during the nebulization, amikacin concentrations are measured in the 24 hours urine collections, which reflected the quantity of dose absorbed via inhalation.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Acute Respiratory Insufficiency</condition>
  <condition>Chronic Respiratory Insufficiency</condition>
  <condition>Bronchospasm and Obstruction</condition>
  <arm_group>
    <arm_group_label>Solo nebulizer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amikacin (500 mg/4 mL) administered with an Aerogen AeroNeb Solo nebulizer associated with a bilevel ventilator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pro nebulizer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amikacin (500 mg/4 mL) administered with an Aerogen AeroNeb Pro nebulizer associated with a bilevel ventilator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NIVO nebulizer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amikacin (500 mg/4 mL) administered with an Aerogen AeroNeb NIVO nebulizer associated with a bilevel ventilator</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nebulizer</intervention_name>
    <description>500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds.</description>
    <arm_group_label>Solo nebulizer</arm_group_label>
    <arm_group_label>Pro nebulizer</arm_group_label>
    <arm_group_label>NIVO nebulizer</arm_group_label>
    <other_name>Vibrating-mesh nebulizers</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No contraindication of amikacin

          -  Written informed consent

          -  Negative pregnant test (for women)

        Exclusion Criteria:

          -  History of respiratory disease

          -  History of renal disease

          -  History of otological disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Bernard Michotte, PhD student</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques Universitaires Saint-Luc (service de pneumologie), Haute Ecole de Santé Vaud (filière physiothérapie), Université Catholique de Louvain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emilie Jossen, BSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ligue Pulmonaire Neuchâteloise</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Roeseler, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Cliniques Universitaires Saint-Luc (service des soins intensifs)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe Liistro, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Université Catholique de Louvain, Institut de Recherche Expérimentale et Clinique (IREC), Pôle de Pneumologie, ORL &amp; Dermatologie, 1200 Brussels, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Grégory Reychler, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cliniques Universitaires Saint-Luc (service de pneumologie), Université Catholique de Louvain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc (Service des soins intensifs)</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2013</study_first_submitted>
  <study_first_submitted_qc>July 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2013</study_first_posted>
  <last_update_submitted>January 29, 2016</last_update_submitted>
  <last_update_submitted_qc>January 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital St Luc, Brussels</investigator_affiliation>
    <investigator_full_name>Jean-Bernard Michotte</investigator_full_name>
    <investigator_title>MSc, PhD Student</investigator_title>
  </responsible_party>
  <keyword>non invasive ventilation</keyword>
  <keyword>single limb circuit ventilator</keyword>
  <keyword>bilevel</keyword>
  <keyword>nebulization</keyword>
  <keyword>nebulizer</keyword>
  <keyword>vibrating mesh nebulizer</keyword>
  <keyword>amikacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
    <mesh_term>Bronchial Spasm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amikacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

